Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1144532 | 0.99 | REN (0.98) | REN | |
| SCHEMBL1144659 | 0.91 | REN (1.00) | REN | |
| Trifluoroacetic Acid SCHEMBL1144385 | 0.87 | REN (0.92) | REN | |
| SCHEMBL1144924 | 0.87 | REN (1.00) | REN | |
| Hydrochloric Acid SCHEMBL1144464 | 0.86 | REN (0.98) | REN | |
| SCHEMBL1144443 | 0.85 | REN (0.86) | REN | |
| SCHEMBL1149511 | 0.84 | REN (1.00) | REN | |
| SCHEMBL8027811 | 0.84 | REN (0.85) | REN | |
| Hydrochloric Acid SCHEMBL1144442 | 0.84 | REN (0.85) | REN | |
| Hydrochloric Acid SCHEMBL1149891 | 0.84 | REN (0.98) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2247575-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095163-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095163-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.